Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical TrialAndrew Ahmann, Vanita R. Aroda, G. Charpentier et al.|Diabetes Care|2017Cited by 574